Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 25, 2016. The report details a significant regulatory milestone for GSK's Vaccines portfolio, specifically the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Shingrix, a candidate vaccine for the prevention of shingles (herpes zoster) in adults aged 50 and over.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a regulatory update regarding product development rather than a financial earnings report.
Material Changes and Regulatory Progress
- EU Submission: GSK submitted an MAA to the EMA for Shingrix on November 25, 2016.
- Global Regulatory Status: This submission follows a filing with the US FDA in October 2016 and a submission to Canadian authorities earlier in November 2016. A submission to Japanese authorities is planned for 2017.
- Clinical Data Basis: The application is supported by a Phase III clinical trial program involving more than 37,000 subjects globally, including the ZOE-50 and ZOE-70 studies published in the New England Journal of Medicine.
Outlook, Management Commentary, and Risks
Management Commentary: Dr. Emmanuel Hanon, Senior Vice President and Head of Vaccines R&D, emphasized that shingles affects up to one in three people during their lifetime and that the vaccine has demonstrated high efficacy in older populations. The submission is viewed as a critical step toward making the vaccine available to prevent shingles and postherpetic neuralgia (PHN).
Product Details: Shingrix is a non-live, recombinant vaccine combining glycoprotein E with the AS01B adjuvant system. It is administered intramuscularly in two doses with a two-to-six-month interval.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in the company's 2015 Annual Report on Form 20-F, including regulatory approval uncertainties and clinical trial outcomes.
Investor Verification Checklist
- Verify the timeline for EMA regulatory review and potential approval dates for Shingrix.
- Confirm the commercial launch strategy and pricing expectations for the EU market following approval.
- Monitor the status of the planned 2017 regulatory submission in Japan.
- Review ongoing clinical trials in immunocompromised populations (e.g., cancer patients, HIV-infected individuals) for potential label expansions.
- Assess the competitive landscape for shingles vaccines in the EU, particularly against existing live-attenuated options.